Introduction Esophageal cancer (EC) is a worldwide healthcare concern and represents an
aggressive malignancy. Squamous cell carcinoma (ESCC) and adenocarcinoma (EAC) are …

Background: Treatment options for advanced gastric esophageal cancer are quite limited.
Chemotherapy is unavoidable at certain stages, and research on targeted therapies has …

Background Accumulating evidence has suggested that aberrant expression of long non-
coding RNAs (lncRNAs) may contribute to cancer progression in association with …

Pharmaceutical therapies are essential for esophageal cancer (EC). For the advanced EC,
the neoadjuvant therapy regimen, including chemotherapy plus radiotherapy and/or …

Background Neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and
monocyte-to-lymphocyte ratio (MLR) are all markers of systemic inflammation response. The …

Esophageal cancer (EC) is the sixth most deadly cancer, and its incidence is still increasing
year by year. Although the researches on the molecular mechanisms of EC have been …

Oncogenic signalling confers tumour-progression advantages; thus, its pharmacological
blockade is the best strategy for cancer chemotherapy. However, drug resistance and …

Abstract Desmoglein‐2 (DSG2) is a transmembrane glycoprotein belonging to the
desmosomal cadherin family, which mediates cell–cell junctions; regulates cell proliferation …

Tumors pose a significant global public health challenge, resulting in numerous fatalities
annually. CD8+ T cells play a crucial role in combating tumors; however, their effectiveness …

Zheng Y, Luo M, Lü M, et al. Onco Targets Ther. 2020; 13: 11193–11209. At the author's
request, we, the Editors and Publisher of OncoTargets and Therapy, have retracted the …